Facebook
Twitter
Telegram
Report an ErrorSorrento Therapeutics Balance Sheet 2011-2024 | SRNE
Annual Balance Sheet Sorrento Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
85.5 M | 59 M | 213 M | 74.5 M | -14.8 M | -35.1 M | -29.8 M | -59.8 M | -26.9 M | -5.09 M | -3.47 M |
Long Term Debt |
111 M | 92.3 M | 199 M | 223 M | 5.21 M | 47.1 M | 4.39 M | 8.83 M | 4.43 M | - | - |
Long Term Debt Current |
11.5 M | 3.63 M | 3.32 M | 10.2 M | - | 209 K | 4.84 M | 3.32 M | 374 K | - | - |
Total Non Current Liabilities |
- | 299 M | 410 M | 355 M | 146 M | 239 M | 172 M | 23.3 M | 20.3 M | - | - |
Total Current Liabilities |
139 M | 96.5 M | 115 M | 61.6 M | 79 M | 76.1 M | 30.9 M | 9.56 M | 5.48 M | 584 K | 359 K |
Total Liabilities |
617 M | 395 M | 525 M | 417 M | 225 M | 315 M | 203 M | 32.8 M | 25.8 M | 584 K | 359 K |
Deferred Revenue |
1.11 M | 4.48 M | 3.64 M | 2.7 M | 3.86 M | 9.67 M | - | - | - | - | - |
Retained Earnings |
-1.39 B | -958 M | -660 M | -368 M | -165 M | -174 M | -113 M | -67.5 M | -32.9 M | -11 M | -6.1 M |
Total Assets |
695 M | 536 M | 558 M | 624 M | 432 M | 402 M | 344 M | 142 M | 92.6 M | 6.78 M | 4.57 M |
Cash and Cash Equivalents |
36.7 M | 56.5 M | 22.5 M | 159 M | 20.4 M | 82.4 M | 39 M | 71.9 M | 31.7 M | 5.09 M | 3.47 M |
Book Value |
78.1 M | 141 M | 32.8 M | 208 M | 207 M | 86.5 M | 141 M | 109 M | 66.8 M | 6.2 M | 4.21 M |
Total Shareholders Equity |
78.7 M | 165 M | 78.6 M | 209 M | 200 M | 80 M | 145 M | 109 M | 66.8 M | 6.2 M | 4.21 M |
All numbers in USD currency
Quarterly Balance Sheet Sorrento Therapeutics
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
21.4 M | 19.1 M | 17.8 M | 83.1 M | 96.1 M | 111 M | 83.5 M | 82.6 M | 80 M | 92.3 M | 92.3 M | 92.3 M | 92.3 M | 199 M | 199 M | 199 M | 199 M | 223 M | 223 M | 223 M | 223 M | 5.21 M | 5.21 M | 5.21 M | 5.21 M | 47.1 M | 47.1 M | 47.1 M | 47.1 M | 4.39 M | 4.39 M | 4.39 M | 4.39 M | 8.83 M | 8.83 M | 8.83 M | 8.83 M | 4.43 M | 4.43 M | 4.43 M | 4.43 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
587 M | 495 M | 485 M | 496 M | 629 M | 617 M | 621 M | 593 M | 383 M | 395 M | 395 M | 395 M | 395 M | 525 M | 525 M | 525 M | 525 M | 417 M | 417 M | 417 M | 417 M | 225 M | 225 M | 225 M | 225 M | 315 M | 315 M | 315 M | 315 M | 203 M | 203 M | 203 M | 203 M | 32.8 M | 32.8 M | 32.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
252 K | 652 K | 281 K | 1.02 M | 673 K | 1.11 M | 2.28 M | 2.64 M | 1.12 M | 4.48 M | 4.48 M | 4.48 M | 4.48 M | 3.64 M | 3.64 M | 3.64 M | 3.64 M | 2.7 M | 2.7 M | 2.7 M | 2.5 M | 3.86 M | 14.7 M | 9.67 M | 9.67 M | 9.67 M | 9.67 M | 9.67 M | 9.67 M | - | 50 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-2.1 B | -1.96 B | -1.74 B | -1.65 B | -1.43 B | -1.39 B | -1.24 B | -1.12 B | -956 M | -958 M | -958 M | -958 M | -958 M | -660 M | -660 M | -660 M | -660 M | -368 M | -368 M | -368 M | -368 M | -165 M | -165 M | -165 M | -165 M | -174 M | -174 M | -174 M | -174 M | -113 M | -113 M | -113 M | -113 M | -67.5 M | -67.5 M | -67.5 M | -67.5 M | -32.9 M | -32.9 M | - | 13.5 M | - | 9.2 M | 7.95 M | - | - | - | - | - |
Total Assets |
460 M | 473 M | 616 M | 632 M | 856 M | 695 M | 753 M | 779 M | 614 M | 536 M | 536 M | 536 M | 536 M | 558 M | 558 M | 558 M | 558 M | 624 M | 624 M | 624 M | 624 M | 432 M | 432 M | 432 M | 432 M | 402 M | 402 M | 402 M | 402 M | 344 M | 344 M | 344 M | 344 M | 142 M | 142 M | 142 M | 142 M | 92.6 M | 92.6 M | 92.6 M | 92.6 M | 6.78 M | 6.78 M | 6.78 M | 6.78 M | 4.57 M | 4.57 M | 4.57 M | 4.57 M |
Cash and Cash Equivalents |
37.7 M | 23.6 M | 70.7 M | 70.3 M | 112 M | 36.7 M | 39.7 M | 77.3 M | 41.7 M | 56.5 M | 56.5 M | 56.5 M | 56.5 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 159 M | 159 M | 159 M | 159 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 82.4 M | 82.4 M | 82.4 M | 82.4 M | 39 M | 39 M | 39 M | 39 M | 71.9 M | 71.9 M | 71.9 M | 71.9 M | 31.7 M | 31.7 M | 31.7 M | 31.7 M | 5.09 M | 5.09 M | 5.09 M | 5.09 M | 3.47 M | 3.47 M | 3.47 M | 3.47 M |
Book Value |
-127 M | -21.7 M | 130 M | 136 M | 226 M | 78.1 M | 131 M | 186 M | 231 M | 141 M | 141 M | 141 M | 141 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 208 M | 208 M | 208 M | 208 M | 207 M | 207 M | 207 M | 207 M | 86.5 M | 86.5 M | 86.5 M | 86.5 M | 141 M | 141 M | 141 M | 141 M | 109 M | 109 M | 109 M | 142 M | 92.6 M | 92.6 M | 92.6 M | 92.6 M | 6.78 M | 6.78 M | 6.78 M | 6.78 M | 4.57 M | 4.57 M | 4.57 M | 4.57 M |
Total Shareholders Equity |
-125 M | -18.6 M | 132 M | 136 M | 226 M | 78.7 M | 131 M | 186 M | 231 M | 165 M | 165 M | 165 M | 165 M | 78.6 M | 78.6 M | 78.6 M | 78.6 M | 209 M | 209 M | 209 M | 209 M | 200 M | 200 M | 200 M | 200 M | 80 M | 80 M | 80 M | 80 M | 145 M | 145 M | 145 M | 145 M | 109 M | 109 M | 109 M | 109 M | 66.8 M | 66.8 M | 66.8 M | 66.8 M | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 4.21 M | 4.21 M | 4.21 M | 4.21 M |
All numbers in USD currency